Nanobiotix S.A.
NBTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. The $1.94B market capitalization puts NBTX squarely in small-cap range for its industry. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer.
Market Cap
$1.94B
Beta
0.57
P/E (TTM)
—
P/E (Fwd)
-112.03
EPS (TTM)
$-0.58
EPS (Fwd)
$-0.34
ROE
—
ROA
-10.1%
Cash
$52.8M
Total Debt
$95.3M
Free CF
-$7.9M
52W Change
315.0%
Annual Financials
Cash vs Debt
Where NBTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NBTX finished 17.31% above its 150-day moving average ($35.52) and 30.10% above its 200-day moving average ($32.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NBTX overbought or oversold?
At the September 3, 2026 close, NBTX's RSI(14) was 56.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $52.8M in cash, though total debt stands at $95.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$7.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
NBTX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Nanobiotix S.A. and its sector.